Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replicel Life Sciences Inc (OP: REPCF )

0.0021 UNCHANGED
Streaming Delayed Price Updated: 12:46 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,400
Open 0.0021
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0021
Today's Range 0.0021 - 0.0021
52wk Range 0.0002 - 0.0778
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RepliCel Provides Corporate Update
Via ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
Via ACCESSWIRE

Performance

YTD
-94.26%
-94.26%
1 Month
N/A
N/A
3 Month
+110.00%
+110.00%
6 Month
+110.00%
+110.00%
1 Year
-96.56%
-96.56%

More News

Read More
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Via ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Material Patent Milestones
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Terminates License Agreement with Shiseido
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Dermal Injector Update
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
Exposures Economy
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Adds Independent Director
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
RepliCel Launches Testing of Dermal Injector Units
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.